A Deeper Look into the Newest Therapies in the Management of Heart Failure: Individualizing Therapy for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

What Managed Care Needs to Know in the Evolving Treatment of Heart Failure: Novel Therapies for Improved Clinical and Economic Outcomes is a 3-part webcast series that will provide attendees
with the latest information in Heart Failure treatment and management.

This is part 1 of the series focusing on an in-depth look at the newer
therapies available in heart failure management.

This activity is an archive from the webinar held May 16, 2018

If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals Corporation

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. HF is responsible for over one million hospitalizations in the U.S. per year which attributes to an estimated $31 billion in costs. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for acute heart failure remain significant. In recent decades, an improved understanding of the pathobiology of HF has led to the introduction of several new classes of medications that have shown improved clinical outcomes in patients with HF. Although these new and emerging therapeutic options have shown to lower mortality their application in clinical practice have been less than ideal as the 5-year mortality rate and patient readmissions for HF remain unacceptably high. In fact, HF is the leading cause of hospitalization among adults over the age of 65 in the U.S. Thus, it is critical that physicians and healthcare providers implement individualized treatment strategies, promote shared decision-making with patients and, ultimately, enhance patient quality of life.

Upon Completion of this activity, participants will be able to:

  • Describe the recently published guideline updates for emerging therapies in HF, including results from pivotal trials and evidence supporting averted HF-related hospitalizations and/or deaths

  • Summarize the mechanisms of action and different clinical attributes, including efficacy and safety, of newer and emerging therapies for the management of HF

  • Evaluate methods for individualizing chronic HF treatment strategies for patients based on specific patient-related factors to control symptoms, reduce hospitalizations, and prevent mortality in patients with reduced ejection fraction

Faculty: Akshay Suvas Desai, MD, MPH
Director, Heart Failure Disease Management
Cardiovascular Division
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School


Dr. Desai has received research support and consulting fees from Novartis Pharmaceuticals. Also, consulting fees from Abbott/St. Jude Medical, AstraZeneca, DalCor Pharma, Novartis Pharmaceuticals, and Relypsa.  His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue